MetLife said it issued an additional $250,000,000 in aggregate principal amount of its 5.300% Senior Notes due 2034 as New Senior Notes, on September 30, 2024. The issuance was made as additional notes under the Senior Indenture.

1. 01

   MetLife said it issued an additional $250,000,000 in aggregate principal amount of its 5.300% Senior Notes due 2034 as New Senior Notes, on September 30, 2024. The issuance was made as additional notes under the Senior Indenture.

2. 02

   The company said it previously issued $500,000,000 in aggregate principal amount of its 5.300% Senior Notes due 2034 under the Forty-Sixth Supplemental Indenture dated June 5, 2024, and that the New Senior Notes were issued under the Forty-Seventh Supplemental Indenture dated September 30, 2024, all of which remain outstanding.

3. 03

   The company said the New Senior Notes were offered and sold under the Form S-S-3 shelf registration statement (File No. 333-268442), which it filed on November 17, 2022, and a prospectus supplement dated September 26, 2024.

4. 04

   MetLife said it entered into an underwriting agreement and a pricing agreement on September 26, 2024 with Morgan Stanley & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the underwriters.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.